Systematic Review

Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis

Liangyu Kang †, Weijing Shang †, Peng Gao, Yaping Wang, Jue Liu and Min Liu *

School of Public Health, Peking University, Beijing 100191, China
* Correspondence: liumin@bjmu.edu.cn; Tel./Fax: +86-10-82805146
† These authors contributed equally to this work.

Abstract: Background: The immunogenicity and safety of COVID-19 vaccines among people living with human immunodeficiency virus (PLWH) are unclear. We aimed to evaluate the immunogenicity and safety of COVID-19 vaccines among PLWH. Methods: We systematically searched PubMed, EMBASE, and Web of Science from 1 January 2020 to 28 April 2022 and included observational studies, randomized clinical trials, and non-randomized clinical trials reporting extractable data about the immunogenicity and safety of COVID-19 vaccines among PLWH. Results: A total of 34 eligible studies covering 4517 PLWH were included. The pooled seroconversion rates among PLWH after the first and second doses were 67.51% (95% confident interval (CI) 49.09–85.93%) and 96.65% (95%CI 95.56–97.75%), respectively. The seroconversion was similar between PLWH and healthy controls after the first (risk ratio (RR) = 0.89, 95%CI 0.76–1.04) and the second (RR = 0.97, 95%CI 0.93–1.00) dose. Moreover, the geometric mean titer (GMT) showed no significant difference between PLWH and healthy controls after the first dose (standardized mean difference (SMD) = 0.30, 95%CI -1.11, 1.70) and the second dose (SMD = -0.06, 95%CI -0.18, 0.05). Additionally, the pooled incidence rates of total adverse events among PLWH after the first and the second dose were 46.55% (95%CI 28.29–64.82%) and 30.96% (95%CI 13.23–48.70%), respectively. There was no significant difference in risks of total adverse events between PLWH and healthy controls after the first (RR = 0.86, 95%CI 0.67–1.10) and the second (RR = 0.88, 95%CI 0.68–1.14) dose. Conclusions: The available evidence suggested that the immunogenicity and safety of COVID-19 vaccines among PLWH were acceptable. There was no significant difference in the seroconversion rates and incidence rates of adverse events of COVID-19 vaccines between PLWH and healthy controls.

Keywords: COVID-19; vaccines; people living with HIV; immunogenicity; safety

1. Introduction

As a new strain of coronavirus that emerged in 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a pandemic of Coronavirus Disease 2019 (COVID-19) around the world. By 23 May 2022, COVID-19 has caused more than 500 million cumulative confirmed cases and 6.28 million cumulative deaths worldwide [1]. It has posed a great challenge to healthcare systems and will continue to be a threat to global health [2,3]. SARS-CoV-2 is a highly transmissible and pathogenic coronavirus that can be transmitted through various routes including air and direct and indirect contact [4]. Noteworthily, compared with the general population, people with other underlying diseases or immunocompromised individuals display greater morbidity and mortality from COVID-19 [5,6].

People living with human immunodeficiency virus (PLWH) might be more susceptible to SARS-CoV-2 infection and more likely to present with severe COVID-19 when infected due to lower immune responses and viral interactions [7,8]. According to a report from
World Health Organization (WHO), human immunodeficiency virus (HIV) infection appears to be a significant independent risk factor for acquiring SARS-CoV-2 infection and is associated with a higher risk of mortality from COVID-19 [7]. Currently, specific medicine to treat COVID-19 has not yet been developed [9], whereas available evidence shows that public health control measures and vaccination are effective measures in reducing morbidity and mortality from the disease [10]. Among all the measures, vaccination is considered to be the most cost-effective and efficient way [11]. As of 23 May 2022, more than 11.8 billion COVID-19 vaccines have been administered globally [1]. The immunogenicity and safety of vaccines are very important to protect people from infection, particularly for PLWH. Although many studies reported data from the general population [12–14], the immunogenicity and safety of vaccination remain unclear in PLWH, which hinders their willingness to actively get vaccinated [15–17].

Studies on the immunogenicity and safety of COVID-19 vaccines among PLWH have been conducted in different countries, but the conclusions are still contradictory. For immunogenicity, some studies showed that protective antibody responses in PLWH were inferior to those in healthy individuals [18,19], while the levels of protective antibodies were similar between the two populations in some randomized clinical trials (RCTs) [20–22]. For safety, some studies found higher incidence rates of adverse events in PLWH [18,23], whereas other studies indicated that the incidence rates of adverse events in PLWH were not different from or even lower than that in the general population [18,22–24]. Therefore, this meta-analysis aimed to systematically evaluate the immunogenicity and safety of COVID-19 among PLWH by reviewing the published relevant studies, thereby providing evidence-based references for PLWH in regard to COVID-19 vaccines.

2. Materials and Methods

2.1. Search Strategy

We conducted the meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [25]. This review was registered with PROSPERO (CRD42022329167). Two researchers (L.K. and W.S.) searched the published studies between 1 January 2020 and 28 April 2022, through PubMed, EMBASE, and Web of Science with English-language restrictions. The search terms included (“SARS-CoV-2” or “COVID-19”) and (“HIV” or “acquired immunodeficiency syndrome”) and (“COVID-19 Vaccines” or “Vaccines” or “Vaccination”). The detailed search strategies are shown in Text S1 in the Supplemental Materials. Two researchers (L.K. and W.S.) reviewed the titles, abstracts, and full texts of articles independently and identified additional studies from the reference lists. Disagreements were resolved by two other reviewers (P.G. and Y.W.).

The primary outcome to evaluate the immunogenicity of COVID-19 vaccines was the seroconversion of neutralizing antibodies to SARS-CoV-2 after a first or second dose, defined as a change from seronegative at baseline to seropositive [26]. The calculation formula was seroconversion rate = the number of people with seroconversion/number of people receiving COVID-19 vaccines × 100%. The geometric mean titer (GMT) of neutralizing antibodies was also used to assess the immunogenicity. The safety of COVID-19 vaccines was determined in this study as the incidence rate of adverse events after vaccination including systemic and local adverse events [27]. The calculation formula was: incidence rate of adverse events = number of people having adverse events/number of people receiving COVID-19 vaccines × 100%.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria consist of (1) studies reporting PLWH receiving any COVID-19 vaccines who had never been infected with SARS-CoV-2; (2) observational studies (cross-sectional studies, case-control studies, and cohort studies), non-randomized clinical trials, and RCTs; (3) studies with extractable data on seroconversion rates, GMT, and incidence rates of adverse events. We excluded the following studies: (1) non-original articles such as reviews, comments, letters, etc.; (2) articles unable to find full text; (3) preprints;
(4) studies with insufficient data to calculate the seroconversion rate and incidence rate of adverse events.

2.3. Data Extraction

The following data were extracted independently by two researchers (L.K. and W.S.) from the included studies: (1) basic information of the studies, including first author, publication year, country, and study design; (2) characteristics of the study population, including the number of PLWH receiving COVID-19 vaccines, and CD4+ T cell counts; (3) relevant information on vaccines, involving types of COVID-19 vaccines, dose, and the time interval between vaccination and antibody testing; (4) outcome for the immunogenicity, including the number of PLWH with seroconversion and GMT of neutralizing antibodies; (5) outcome for the safety, involving the number of PLWH having adverse events. If available, we also collected the data on the immunogenicity and safety of COVID-19 vaccines among healthy controls in cohort studies, non-randomized clinical trials, and RCTs, including the number of healthy controls receiving COVID-19 vaccines, number of healthy controls with seroconversion, and number of healthy controls having adverse events.

2.4. Risk of Bias Assessment

We evaluated the risk of bias using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) [28] for RCTs, Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool [29] for non-randomized clinical trials, Newcastle–Ottawa scale [30] for cohort studies and case-control studies, and Agency for Healthcare Research and Quality (AHRQ) [31] for cross-sectional studies. Two researchers (L.K. and W.S.) performed the quality assessment independently. Disagreements were resolved by two other reviewers (P.G. and Y.W.).

2.5. Data Synthesis and Statistical Analysis

Based on available data about seroconversion rates and incidence rates of adverse events from observational studies, non-randomized clinical trials, and RCTs, we estimated the pooled seroconversion rates and incidence rates of adverse events as well as their 95% confidence intervals (CIs) among PLWH receiving a first or second dose of COVID-19 vaccines, using the inverse variance-weighted random-effects model [32].

For cohort studies, non-randomized clinical trials, and RCTs with healthy controls, the crude risk ratios (RRs) of seroconversion and adverse events were calculated using the following formula.

\[ RR = \frac{N_p}{N_c} / \frac{n_p}{n_c} \]  \hspace{1cm} (1)

The \( n_p \) represented the number of PLWH with seroconversion or having adverse events; \( N_p \) represented the number of PLWH receiving COVID-19 vaccines; \( n_c \) represented the number of healthy controls with seroconversion or having adverse events; \( N_c \) represented the number of healthy controls receiving COVID-19 vaccines. The Mantel-Haenszel random-effects method [33] was adopted to calculate the pooled RRs and their 95% CIs, to compare the seroconversion and safety between PLWH and a healthy population. Both RR and the lower limit of its 95%CI > 1 indicated that PLWH had a higher risk of seroconversion and adverse events after vaccination compared with healthy controls; both RR and the upper limit of its 95%CI < 1 indicated that PLWH had a lower risk; other situations suggested no significant difference between PLWH and healthy controls.

For observational studies and trials with data about GMT of neutralizing antibodies, standardized mean difference (SMD) was used to compare GMT among PLWH with healthy controls. The heterogeneity among studies was assessed using \( I^2 \) values, and \( I^2 \geq 50\% \) was regarded as significant heterogeneity [34].
We conducted subgroup analyses by continent, study design, vaccine type, time interval between vaccination and antibody testing, and CD4+ T cell counts. We used the Q test to conduct subgroup comparisons and variables were considered significant between subgroups if the subgroup difference p value was less than 0.05. The studies with a high risk of bias were excluded for sensitivity analysis. We also performed sensitivity analysis by excluding studies with a number of PLWH < 100 as studies with small sizes are susceptible to selection bias and tend to have larger treatment effects than large studies [35]. Publication bias was assessed by funnel plot and Egger’s regression test. When publication bias was suspected based on either the funnel plot or Egger’s test, we conducted a sensitivity analysis using the trim-and-fill method to re-estimate the pooled effect size after imputing potentially missing studies [36]. Two-sided p < 0.05 indicated statistical significance. All analyses were performed on R (version 4.0.5) using the meta and forestplot packages.

3. Results

3.1. Characteristics of Included Studies

We identified 4250 studies through databases search and reference lists of articles and reviews. 1088 duplicates were excluded. After reading titles and abstracts, we excluded 3042 irrelevant articles. Among the 120 studies under full-text review, 86 studies were excluded. The final meta-analysis comprised 34 eligible studies, including 22 articles [21–23,37–55] for only immunogenicity, three articles [24,56,57] for only safety, and nine articles [18,20,58–64] for both immunogenicity and safety (Figure S1).

Among the 34 studies, seven (20.59%) were cross-sectional studies, one (2.94%) was a case-control study, 18 (52.94%) were cohort studies, six (17.65%) were non-randomized clinical trials, two (5.88%) were RCTs. 13 (38.24%) studies were conducted in Europe, 10 (29.41%) in Asia, seven (20.59%) in North America, two (5.88%) in South America, and two (5.88%) in Africa. 13 (38.24%) studies were assessed as low risk of bias, 17 (50.00%) as the moderate risk of bias, and four (11.76%) as high risk of bias. Characteristics of included studies are shown in Tables S1–S2, and results of risk of bias assessment are detailed in Tables S3–S7.

3.2. Seroconversion Rates among PLWH

In 11 studies involving 995 PLWH receiving the first dose of COVID-19 vaccines, the pooled seroconversion rate was 67.51% (95%CI 49.09–85.93%), with high heterogeneity among studies (I² = 99.0%) (Figure 1). The subgroup analyses showed significant differences in seroconversion rates among different continents, study designs, and vaccine types (p < 0.05). The seroconversion rates were relatively lower in South America (19.16%, 95%CI 13.89–24.43%), cross-sectional studies (45.14%, 95%CI 19.42–70.85%), and PLWH receiving inactivated virus vaccines (21.69%, 95%CI 15.74–27.63%) (Table 1).

In 28 studies involving 3432 PLWH receiving the second dose of COVID-19 vaccines, the pooled seroconversion rate was 96.65% (95%CI 95.56–97.75%), with high heterogeneity among studies (I² = 85.2%) (Figure 1). Significant subgroup differences were observed in different continents, study designs, vaccine types, time intervals between vaccination and antibody testing, and CD4+ T cell counts (p < 0.05). The PLWH in South America (81.64%, 95%CI 62.33–100.00%), receiving inactivated virus vaccines (88.62%, 95%CI 83.21–94.03%), whose time intervals between vaccination and antibody testing > 28 days (92.89%, 95%CI 89.40–96.38%), and with CD4+ T cell counts < 500 cells/µL (91.44%, 95%CI 85.77–97.11%) had lower seroconversion rates (Table 1).
Figure 1. The seroconversion rates of SARS-CoV-2 antibodies among people living with HIV. PLWH: people living with HIV; CI: confidence interval.
Table 1. The seroconversion rates of SARS-CoV-2 antibodies among people living with HIV by subgroup.

|                                | No. of Studies | No. of PLWH | Seroconversion Rate (%) (95%CI) | $I^2$ (%) | $p$ Value for Heterogeneity | Weight (%) | $p$ Value for Subgroup Differences |
|--------------------------------|----------------|-------------|---------------------------------|-----------|----------------------------|------------|-----------------------------------|
| **The first dose**             |                |             |                                 |           |                           |            |                                   |
| Overall                        | 11             | 995         | 67.51 (49.09–85.93)             | 99.0      | <0.001                     | 100.0      | <0.001                            |
| Continent                      |                |             |                                 |           |                           |            |                                   |
| Africa                         | 2              | 44          | 92.15 (78.66–100.00)            | 52.6      | 0.147                      | 17.9       |                                   |
| Asia                           | 2              | 77          | 26.95 (17.08–36.83)             | 0.0       | 0.457                      | 17.7       |                                   |
| Europe                         | 3              | 283         | 76.51 (64.51–88.51)             | 80.9      | 0.005                      | 27.5       |                                   |
| North America                  | 3              | 276         | 85.19 (78.66–100.00)            | 96.3      | <0.001                     | 27.7       |                                   |
| South America                  | 1              | 214         | 19.16 (13.89–24.43)             | NA        | NA                         | 9.3        |                                   |
| Study design                   |                |             |                                 |           |                           |            |                                   |
| Cross-sectional study          | 2              | 113         | 45.14 (19.42–70.85)             | 86.5      | 0.006                      | 17.9       |                                   |
| Cohort study                   | 6              | 796         | 73.71 (49.11–98.30)             | 99.4      | <0.001                     | 55.3       |                                   |
| Non-randomized clinical trial  | 2              | 50          | 61.81 (0.00–100.00)             | 98.3      | <0.001                     | 17.8       |                                   |
| Randomized clinical trial      | 1              | 36          | 86.11 (74.81–97.41)             | NA        | NA                         | 9.0        |                                   |
| **Vaccine type**               |                |             |                                 |           |                           |            |                                   |
| Adenovirus vector vaccines     | 2              | 44          | 92.15 (78.66–100.00)            | 52.6      | 0.147                      | 19.7       | <0.001                            |
| Inactivated virus vaccines     | 3              | 291         | 21.69 (15.74–27.63)             | 17.2      | 0.299                      | 29.9       |                                   |
| mRNA vaccines                  | 5              | 568         | 76.81 (64.23–89.38)             | 93.4      | <0.001                     | 50.4       |                                   |
| **Time interval between**      |                |             |                                 |           |                           |            |                                   |
| vaccination and antibody testing|                |             |                                 |           |                           |            |                                   |
| <28 days                       | 5              | 568         | 76.81 (64.23–89.38)             | 93.4      | <0.001                     | 50.1       |                                   |
| ≥28 days                       | 5              | 392         | 65.55 (22.55–100.00)            | 99.5      | <0.001                     | 49.9       |                                   |
| **CD4+ T-cell counts**         |                |             |                                 |           |                           |            |                                   |
| <500 cells/µL                  | 1              | 64          | 15.62 (6.73–24.52)              | NA        | NA                         | NA         |                                   |
| ≥500 cells/µL                  | 1              | 150         | 20.67 (14.19–27.15)             | NA        | NA                         | NA         |                                   |
| **The second dose**            |                |             |                                 |           |                           |            |                                   |
| Overall                        | 28             | 3432        | 96.65 (95.56–97.75)             | 85.2      | <0.001                     | 100.0      |                                   |
| Continent                      |                |             |                                 |           |                           |            |                                   |
| Africa                         | 1              | 32          | 93.75 (85.36–100.00)            | NA        | NA                         | 1.4        |                                   |
| Asia                           | 9              | 913         | 94.83 (91.82–97.84)             | 83.8      | <0.001                     | 31.1       |                                   |
| Europe                         | 11             | 1890        | 98.87 (97.96–99.77)             | 74.1      | 0.007                      | 50.3       |                                   |
| North America                  | 5              | 338         | 93.11 (86.66–99.56)             | 85.9      | <0.001                     | 12.9       |                                   |
| South America                  | 2              | 259         | 81.64 (62.33–100.00)            | 89.4      | 0.002                      | 4.3        |                                   |
| Study design                   |                |             |                                 |           |                           |            |                                   |
| Cross-sectional study          | 6              | 1059        | 97.74 (95.80–99.67)             | 72.3      | 0.003                      | 26.4       |                                   |
| Cohort study                   | 14             | 1659        | 95.55 (93.45–97.65)             | 87.4      | <0.001                     | 51.3       |                                   |
| Case-control study             | 1              | 100         | 88.00 (81.63–94.37)             | NA        | NA                         | 2.1        |                                   |
| Non-randomized clinical trial  | 5              | 241         | 90.53 (83.83–97.21)             | 87.0      | <0.001                     | 12.0       |                                   |
| Randomized clinical trial      | 2              | 373         | 98.34 (92.92–100.00)            | 53.0      | 0.145                      | 8.2        |                                   |
| **Vaccine type**               |                |             |                                 |           |                           |            |                                   |
| Adenovirus vector vaccines     | 3              | 128         | 93.68 (84.63–100.00)            | 79.0      | 0.009                      | 8.2        |                                   |
| Inactivated virus vaccines     | 9              | 734         | 88.62 (83.21–94.03)             | 89.6      | <0.001                     | 24.2       |                                   |
| mRNA vaccines                  | 13             | 1614        | 99.14 (98.43–99.85)             | 57.6      | 0.005                      | 67.6       |                                   |
| **Time interval between**      |                |             |                                 |           |                           |            |                                   |
| vaccination and antibody testing|                |             |                                 |           |                           |            |                                   |
| <14 days                       | 8              | 653         | 98.66 (96.78–100.00)            | 73.7      | <0.001                     | 38.8       |                                   |
| 15–28 days                     | 6              | 620         | 95.34 (92.04–98.83)             | 87.1      | <0.001                     | 27.8       |                                   |
| >28 days                       | 9              | 1070        | 92.89 (89.40–96.38)             | 89.7      | <0.001                     | 33.3       |                                   |
| **CD4+ T-cell counts**         |                |             |                                 |           |                           |            |                                   |
| <500 cells/µL                  | 4              | 224         | 91.44 (85.77–97.11)             | 58.6      | 0.064                      | 42.6       |                                   |
| ≥500 cells/µL                  | 3              | 270         | 97.99 (95.09–100.00)            | 65.5      | 0.055                      | 57.4       |                                   |

PLWH: people living with HIV; CI: confidence interval.

3.3. Comparison of Seroconversion between PLWH and Healthy Controls

In nine studies consisting of 882 PLWH and 1160 healthy controls after the first dose of COVID-19 vaccines, the risk of achieving seroconversion was not significantly different between PLWH and healthy controls (RR = 0.89, 95%CI 0.76–1.04), with high heterogeneity among studies ($I^2 = 93.1\%$) (Figure 2). The subgroup analyses showed significant differences in RRs among different continents and vaccine types ($p < 0.05$). The risk of seroconversion...
among PLWH in Asia (RR = 0.33, 95%CI 0.18–0.60), in South America (RR = 0.50, 95%CI 0.36–0.68), and receiving inactivated virus vaccines (RR = 0.44, 95%CI 0.31–0.63) was lower than that among healthy controls (Table 2).

Figure 2. Risk ratios for seroconversion among people living with HIV compared with healthy controls after a first or second dose of COVID-19 vaccine. PLWH: people living with HIV; ns: number of people with seroconversion; N: group size; RR: risk ratio; CI: confidence interval.

| The first dose                  | PLWH(n/N) | Healthy controls(n/N) | RR(95%CI) | Weight(%) |
|--------------------------------|-----------|-----------------------|-----------|-----------|
| Brumme et al (2022) [39]       | 91/92     | 135/137               | 1.00 (0.97–1.03) | 14.02     |
| Feng et al (2022) [40]         | 104/22    | 20/28                 | 0.34 (0.18–0.60) | 4.83      |
| Hee et al (2022) [43]          | 21/29     | 35/53                 | 1.23 (1.13–1.34) | 13.56     |
| Jedee et al (2022) [45]        | 60/88     | 41/41                 | 0.64 (0.55–0.75) | 12.40     |
| Khan et al (2021) [46]         | 8/8       | 10/24                 | 1.48 (1.13–1.96) | 9.92      |
| Madhi et al (2021) [23]        | 31/36     | 18/23                 | 1.10 (0.86–1.42) | 10.43     |
| Nault et al (2022) [49]        | 100/106   | 19/20                 | 0.99 (0.89–1.11) | 13.19     |
| Netto et al (2022) [51]        | 412/14    | 114/295               | 0.50 (0.36–0.68) | 9.19      |
| Oya et al (2022) [51]          | 23/27     | 54/54                 | 0.85 (0.73–1.00) | 12.45     |
| **Overall**                    | 578/882   | 772/1160              | 0.89 (0.76–1.04) | 100.00    |

| The second dose                 | PLWH(n/N) | Healthy controls(n/N) | RR(95%CI) | Weight(%) |
|--------------------------------|-----------|-----------------------|-----------|-----------|
| Antinor et al (2022) [37]      | 155/160   | 169/168               | 0.97 (0.94–1.00) | 6.93      |
| Ao et al (2022) [58]           | 121/139   | 119/120               | 0.88 (0.82–0.94) | 5.70      |
| Alcobs et al (2022) [36]       | 39/55     | 60/65                 | 0.77 (0.64–0.92) | 2.34      |
| Bergman et al (2021) [59]      | 78/79     | 78/76                 | 0.99 (0.96–1.01) | 6.99      |
| Brumme et al (2022) [39]       | 91/92     | 136/137               | 1.00 (0.97–1.02) | 6.97      |
| Feng et al (2022) [40]         | 29/42     | 20/28                 | 0.97 (0.71–1.32) | 1.04      |
| Frater et al (2021) [80]       | 54/54     | 49/50                 | 1.02 (0.98–1.06) | 6.63      |
| Haidar et al (2022) [41]       | 75/94     | 159/172               | 0.86 (0.77–0.96) | 4.12      |
| Han et al (2022) [18]          | 47/47     | 18/18                 | 1.00 (0.92–1.08) | 5.13      |
| Hee et al (2022) [43]          | 269/269   | 536/538               | 1.00 (1.00–1.01) | 7.25      |
| Jedee et al (2022) [45]        | 50/52     | 41/41                 | 0.96 (0.91–1.02) | 6.15      |
| Levy et al (2021) [20]         | 139/143   | 258/261               | 0.98 (0.95–1.01) | 6.66      |
| Lv et al (2022) [48]           | 19/24     | 21/24                 | 0.90 (0.70–1.17) | 1.44      |
| Madhi et al (2021) [23]        | 30/32     | 22/23                 | 0.98 (0.87–1.11) | 3.68      |
| Netto et al (2022) [51]        | 185/204   | 269/274               | 0.94 (0.89–0.98) | 6.31      |
| Oya et al (2022) [51]          | 23/23     | 52/52                 | 1.00 (0.94–1.07) | 5.74      |
| Rahav et al (2021) [82]        | 154/156   | 269/272               | 1.00 (0.98–1.02) | 7.05      |
| Woldemerskel et al (2022) [54] | 12/12     | 17/17                 | 1.00 (0.87–1.15) | 3.30      |
| Wong et al (2022) [55]         | 202/213   | 78/80                 | 0.97 (0.93–1.02) | 6.38      |
| **Overall**                    | 1772/1890 | 2366/2418             | 0.97 (0.93–1.00) | 100.00    |
Table 2. Risk ratios for seroconversion among full-vaccinated people living with HIV compared with healthy controls by subgroup.

| No. of Studies | No. of PLWH | RR (95%CI) | I² (%) | p Value for Heterogeneity | Weight (%) | p Value for Subgroup Differences |
|----------------|-------------|------------|--------|---------------------------|------------|----------------------------------|
| **The first dose** | | | | | | |
| **Overall** | 9 | 882 | 0.89 (0.76–1.04) | 93.1 | <0.001 | 100.0 | <0.001 |
| **Continent** | | | | | | | |
| Africa | 2 | 44 | 1.27 (0.93–1.74) | 64.3 | 0.094 | 20.4 | 4.8 |
| Asia | 1 | 42 | 0.33 (0.18–0.60) | NA | NA | 4.8 | 4.8 |
| Europe | 3 | 384 | 0.88 (0.59–1.33) | 96.8 | <0.001 | 20.4 | 38.4 |
| North America | 2 | 198 | 1.00 (0.97–1.03) | 0.0 | 0.027 | 27.2 | 9.2 |
| South America | 1 | 214 | 0.50 (0.36–0.68) | NA | NA | 9.2 | 9.2 |
| **Study design** | | | | | | | |
| Cohort study | 6 | 796 | 0.87 (0.73–1.02) | 94.2 | <0.001 | 74.8 | 29.1 |
| Non-randomized clinical trial | 2 | 50 | 0.71 (0.09–5.87) | 97.6 | <0.001 | 14.8 | 4.8 |
| Randomized clinical trial | 1 | 36 | 1.10 (0.86–1.42) | NA | NA | 10.4 | 10.4 |
| **Vaccine type** | | | | | | | |
| Adenovirus vector vaccines | 2 | 44 | 1.27 (0.93–1.74) | 64.3 | 0.094 | 24.7 | <0.001 |
| Inactivated virus vaccines | 2 | 256 | 0.44 (0.31–0.63) | 27.6 | 0.240 | 19.3 | 19.3 |
| mRNA vaccines | 4 | 490 | 0.91 (0.69–1.20) | 95.2 | <0.001 | 56.0 | 20.4 |
| **Time interval between vaccination and antibody testing** | | | | | | | |
| <28 days | 4 | 490 | 0.91 (0.69–1.20) | 95.2 | <0.001 | 51.6 | 51.6 |
| ≥28 days | 5 | 392 | 0.78 (0.31–1.94) | 98.8 | <0.001 | 48.4 | 48.4 |
| **CD4+ T-cell count** | | | | | | | |
| <500 cells/µL | 1 | 64 | 0.40 (0.22–0.73) | NA | NA | 25.7 | 25.7 |
| ≥500 cells/µL | 1 | 150 | 0.53 (0.38–0.76) | NA | NA | 74.3 | 74.3 |
| **The second dose** | | | | | | | |
| **Overall** | 19 | 1890 | 0.97 (0.93–1.00) | 94.2 | <0.001 | 100.0 | 0.643 |
| **Continent** | | | | | | | |
| Africa | 1 | 32 | 0.98 (0.87–1.11) | NA | NA | 3.7 | 3.7 |
| Asia | 7 | 764 | 0.97 (0.93–1.01) | 69.8 | 0.003 | 33.5 | 33.5 |
| Europe | 6 | 637 | 0.99 (0.97–1.02) | 81.6 | <0.001 | 39.7 | 39.7 |
| North America | 3 | 198 | 0.95 (0.97–1.03) | 92.9 | <0.001 | 14.4 | 14.4 |
| South America | 2 | 259 | 0.86 (0.70–1.07) | 80.5 | 0.024 | 8.7 | 8.7 |
| **Study design** | | | | | | | |
| Cohort study | 14 | 1659 | 0.96 (0.92–1.00) | 96.1 | <0.001 | 80.2 | 0.342 |
| Non-randomized clinical trial | 4 | 199 | 1.00 (0.97–1.03) | 17.9 | 0.301 | 16.1 | 16.1 |
| Randomized clinical trial | 1 | 32 | 0.98 (0.87–1.11) | NA | NA | 3.7 | 3.7 |
| **Vaccine type** | | | | | | | |
| Adenovirus vector vaccines | 2 | 86 | 1.02 (0.98–1.06) | 0.0 | 0.444 | 10.8 | 10.8 |
| Inactivated virus vaccines | 7 | 585 | 0.92 (0.87–0.97) | 47.7 | 0.075 | 25.4 | 25.4 |
| mRNA vaccines | 9 | 1033 | 0.99 (0.97–1.00) | 72.9 | <0.001 | 63.8 | 63.8 |
| **Time interval between vaccination and antibody testing** | | | | | | | |
| ≤14 days | 7 | 598 | 0.98 (0.93–1.04) | 43.8 | <0.001 | 43.8 | 43.8 |
| 15–28 days | 4 | 480 | 0.96 (0.90–1.02) | 84.9 | <0.001 | 22.8 | 22.8 |
| >28 days | 6 | 587 | 0.95 (0.91–1.00) | 81.9 | <0.001 | 33.4 | 33.4 |
| **CD4+ T-cell count** | | | | | | | |
| <500 cells/µL | 3 | 170 | 0.93 (0.86–1.01) | 69.0 | 0.040 | 48.9 | 0.178 |
| ≥500 cells/µL | 2 | 219 | 0.98 (0.96–1.01) | 0.0 | 0.501 | 51.1 | 51.1 |

PLWH: people living with HIV; RR: risk ratio; CI: confidence interval.

In 19 studies consisting of 1890 PLWH and 2418 healthy controls after the second dose of COVID-19 vaccines, the risk of seroconversion was similar between PLWH and healthy controls (RR = 0.97, 95%CI 0.93–1.00), with high heterogeneity among studies (I² = 94.2%) (Figure 2). The risk of seroconversion among PLWH was not significantly different from healthy controls in each subgroup (RRs’ 95%CIs cross 1), except for PLWH who received inactivated virus vaccines (RR = 0.92, 95%CI 0.87–0.97) (Table 2).

3.4. Geometric Mean Titers between PLWH and Healthy Controls

In two studies involving 137 PLWH and 73 healthy controls after the first dose of COVID-19 vaccines, the GMT showed a nonsignificant difference between the two groups (SMD = 0.30, 95%CI −1.11, 1.70). In five studies consisting of 571 PLWH and 681 healthy controls after the second dose of COVID-19 vaccines, the GMT among PLWH was not
significantly different from that among healthy controls (SMD = −0.06, 95% CI −0.18, 0.05) (Figure S2).

3.5. Safety of COVID-19 Vaccines among PLWH

After the first dose of COVID-19 vaccines, the pooled incidence rates of total adverse events, systemic adverse events, and local adverse events were 46.55% (95% CI 28.29–64.82%), 39.48% (95% CI 17.58–61.38%), and 42.94% (95% CI 21.14–64.74%), respectively (Figure S3). There was no significant difference in risks of total adverse events (RR = 0.86, 95% CI 0.67–1.10), systemic adverse events (RR = 0.95, 95% CI 0.79–1.14), and local adverse events (RR = 0.75, 95% CI 0.47–1.17) between PLWH and healthy controls (Figure 3).

| Author (year) | PLWH(na/N) | Healthy controls(na/N) | RR(95%CI) | Weight(%) |
|---------------|------------|------------------------|-----------|-----------|
| **The first dose** | | | | |
| Netto et al. (2022) [61] | 60/169 | 122/296 | 0.86 (0.67–1.10) | 100.00 |
| **Overall** | 60/169 | 122/296 | 0.86 (0.67–1.10) | 100.00 |
| **The second dose** | | | | |
| Bergman et al. (2021) [59] | 1/79 | 0/78 | 2.96 (0.12–71.62) | 0.54 |
| Ao et al. (2022) [58] | 18/139 | 16/120 | 0.97 (0.52–1.82) | 18.38 |
| Netto et al. (2022) [61] | 55/189 | 91/265 | 0.85 (0.64–1.12) | 81.08 |
| **Overall (P=0.0%, p=0.696)** | 74/407 | 107/463 | 0.88 (0.68–1.14) | 100.00 |

| Author (year) | PLWH(na/N) | Healthy controls(na/N) | RR(95%CI) | Weight(%) |
|---------------|------------|------------------------|-----------|-----------|
| **Systemic adverse events** | | | | |
| Frater et al. (2021) [60] | 40/53 | 43/50 | 0.88 (0.73–1.06) | 38.56 |
| Netto et al. (2022) [61] | 55/169 | 97/296 | 0.99 (0.76–1.30) | 61.44 |
| **Overall (P=0.0%, p=0.385)** | 95/222 | 140/346 | 0.95 (0.79–1.14) | 100.00 |
| **The second dose** | | | | |
| Frater et al. (2021) [60] | 22/51 | 32/49 | 0.66 (0.45–0.96) | 23.85 |
| Rahav et al. (2021) [62] | 28/143 | 57/272 | 0.93 (0.62–1.40) | 28.70 |
| Netto et al. (2022) [61] | 49/189 | 79/265 | 0.86 (0.63–1.17) | 47.45 |
| **Overall (P=0.0%, p=0.399)** | 98/383 | 167/586 | 0.84 (0.66–1.03) | 100.00 |

| Author (year) | PLWH(na/N) | Healthy controls(na/N) | RR(95%CI) | Weight(%) |
|---------------|------------|------------------------|-----------|-----------|
| **Local adverse events** | | | | |
| Frater et al. (2021) [60] | 40/53 | 44/50 | 0.86 (0.71–1.03) | 60.21 |
| Netto et al. (2022) [61] | 21/169 | 61/296 | 0.60 (0.38–0.95) | 39.79 |
| **Overall (P=71.7%, p=0.060)** | 61/222 | 105/346 | 0.75 (0.47–1.17) | 100.00 |
| **The second dose** | | | | |
| Frater et al. (2021) [60] | 22/51 | 37/49 | 0.57 (0.40–0.81) | 30.83 |
| Rahav et al. (2021) [62] | 58/143 | 199/272 | 0.55 (0.45–0.88) | 43.36 |
| Netto et al. (2022) [61] | 30/189 | 45/265 | 0.93 (0.61–1.43) | 25.81 |
| **Overall (P=59.7%, p=0.084)** | 110/383 | 281/586 | 0.64 (0.48–0.86) | 100.00 |

Figure 3. Risk ratios for adverse events among people living with HIV compared with healthy controls after a first or second dose of COVID-19 vaccine. PLWH: people living with HIV; na: number of people reported adverse events; N: group size; RR: risk ratio; CI: confidence interval.
After the second dose of COVID-19 vaccines, the pooled incidence rates of total adverse events, systemic adverse events, and local adverse events were 30.96% (95% CI 13.23–48.70%), 33.75% (95% CI 22.90–44.60%), and 36.98% (95% CI 19.83–54.13%), respectively (Figure S3). The risks of total adverse events (RR = 0.88, 95% CI 0.68–1.14) and systemic adverse events (RR = 0.84, 95% CI 0.68–1.03) in PLWH were compatible with those in healthy controls, and the risk of local adverse events was even slightly lower in PLWH (Figure 3).

3.6. Sensitivity Analysis and Publication Bias

After excluding four studies with a high risk of bias, the pooled seroconversion rates, RRs for seroconversion, and incidence rates of adverse events were close to the original results (Figures S4–S6). After excluding studies with the number of PLWH < 100, the results also remained stable (Figures S7–S9). The funnel plots and Egger’s test suggested that there might be publication bias in the meta-analyses of seroconversion rates and RRs for seroconversion after the second dose of COVID-19 vaccines (Figures S10–S12). Using the trim-and-fill method to address publication bias, the pooled seroconversion rate (99.23%, 95% CI 98.03–100.00%) and RR (1.00, 95% CI 0.98–1.02) were very close to the original results.

4. Discussion

In this systematic review and meta-analysis, we found that the pooled seroconversion rate among PLWH after the second dose (96.65%) was higher than that after the first dose (67.51%). Subgroup analyses showed that PLWH receiving inactivated virus vaccines had lower seroconversion rates after both doses, and lower seroconversion rates were observed among PLWH whose time intervals between vaccination and antibody testing > 28 days and CD4+ T cell counts < 500 cells/µL. Compared with healthy controls, the risk of seroconversion among PLWH receiving inactivated virus vaccines was lower (RR = 0.92, 95% CI 0.87–0.97) than that among healthy controls. Moreover, the GMT showed no significant difference between PLWH and healthy controls after the first dose and the second dose. In addition, we also found there was no significant difference in the safety of COVID-19 vaccines between PLWH and healthy controls. The pooled incidence rates of total adverse events after the first dose and after the second dose were 46.55% and 30.96%, respectively. PLWH even had a slightly lower risk of local adverse events than healthy controls (RR = 0.64, 95% CI 0.48–0.86).

Our results suggested that the seroconversion of COVID-19 vaccines was compatible between PLWH and healthy individuals, and the pooled seroconversion rate after the second dose was higher than that after the first dose among PLWH. Nowadays, there are very few relevant systematic reviews. Lee et al. [65] conducted a systematic review on the efficacy of COVID-19 vaccines in immunocompromised patients and found the seroconversion in PLWH was similar to the immunocompetent population after the second dose (RR = 1.00, 95% CI 0.98–1.01). Our results were consistent with Lee’s study. Furthermore, our study gave a more comprehensive picture of the immunogenicity in PLWH by including more studies and a larger PLWH population. Our findings highlighted the importance of receiving a second dose of the COVID-19 vaccine in PLWH.

In the subgroup analyses, we found that PLWH receiving inactivated virus vaccines had lower seroconversion rates after both doses, and their risk of seroconversion was lower than healthy controls. Currently, there has been no systematic review reporting the immunogenicity of different types of COVID-19 vaccines among PLWH. Cheng et al. [66] evaluated the effectiveness and safety of different types of COVID-19 vaccines through a systematic review of the general population and found that all the vaccines had excellent effectiveness and acceptable risk of adverse events. Among various types of COVID-19 vaccines, the inactivated vaccine had lower effectiveness but higher safety. Additionally, lower seroconversion rates were observed among PLWH whose time intervals between vaccination and antibody testing > 28 days and CD4+ T cell counts < 500 cells/µL. Several observational studies and non-randomized clinical trials [18,40,58] also showed that the
concentration of protective antibodies decreased significantly in PLWH after vaccination than that in healthy individuals. Therefore, booster vaccination might be important to prevent primary and re-infection of SARS-CoV-2 in PLWH. The immune system of PLWH is weakened due to the declined number of CD4+ T cells. Correspondingly, their impaired cellular and humoral immunity might limit the immune responses elicited by vaccines [67]. Netto et al. [61] conducted a prospective cohort study covering 215 PLWH and found that PLWH whose CD4+ T cell counts were less than 500 cells/µL had lower seroconversion rates than those with CD4+ T cell counts of at least 500 cells/µL. These findings indicated strategies should be developed to improve vaccine-induced immunogenicity in PLWH, especially in the subgroup with lower CD4+ T cell counts. Furthermore, the immune-related functions and HIV viral load in PLWH should be monitored carefully before and after vaccination.

In this study, we also found that there was no significant difference in the safety of COVID-19 vaccines between PLWH and health controls. The pooled incidence rates of total adverse events after the first dose and the second dose were 46.55% and 30.96%, respectively. The risk of local adverse events was even slightly lower in PLWH (RR = 0.64, 95%CI 0.48–0.86) compared with healthy controls. The pooled incidence rates of adverse events in PLWH were close to results from previous studies in healthy populations. A meta-analysis including 12 clinical trials covering 22802 vaccine recipients indicated that 46.3% (95% CI 38.2–54.3%) of them reported at least one systemic adverse event and 66.7% (95%CI 53.2–80.3%) reported at least one local adverse event after the first dose [27]. Moreover, we found a lower incidence rate of adverse events among PLWH after the second dose in comparison to that after the first dose, consistent with several published studies [12,57,61]. The reason might be that people having fewer adverse events after the first dose were more likely to receive a second dose. Nevertheless, our study demonstrated the safety of COVID-19 vaccines and would be helpful to mitigate vaccine hesitancy and concerns in PLWH.

To our knowledge, this is the first study to systematically evaluate the immunogenicity and safety of the COVID-19 vaccine in PLWH. Relevant studies on PLWH receiving a first or second dose of the COVID-19 vaccine published from 1 January 2020 to 29 April 2022 were included. We estimated the pooled seroconversion rates of protective antibodies and incidence rates of adverse events among PLWH and performed subgroup analyses among different continents, study designs, vaccine types, and CD4+ T cell counts. We also found that the immunogenicity and safety of COVID-19 vaccines were similar between PLWH and healthy controls. Our results could help reduce vaccine hesitancy and concerns among PLWH and provide evidence-based references for policymakers to make vaccination strategies.

This study has several limitations. First, we did not evaluate the immunogenicity and safety of booster doses of COVID-19 vaccines in PLWH due to lacking original studies. More studies on booster vaccination among PLWH are needed. Second, the majority of the included studies were conducted in Europe and Asia, while there were limited studies in Africa where the disease burden of HIV is heavy. Therefore, our results should be interpreted with caution when applying to PLWH in Africa. In the future, relevant studies in Africa are required to further complement the immunogenicity and safety of COVID-19 vaccines among PLWH. Third, the high heterogeneity among studies which might be related to different study locations, periods, and sample sizes, made the results in need of future verification.

5. Conclusions

In conclusion, the available evidence suggested that the immunogenicity and safety of COVID-19 vaccines among PLWH were acceptable. There was no significant difference in the seroconversion rates and incidence rates of adverse events of COVID-19 vaccines between PLWH and healthy controls. Further studies on the immunogenicity, effectiveness and safety of COVID-19 vaccines should focus on various types of vaccines, PLWH with
different CD4+ T cell counts, and booster vaccination, especially in countries and regions with heavy HIV burdens.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines10091569/s1, Text S1: Detailed Search Strategies; Figure S1: Flowchart of study selection; Figure S2: The SMD of geometric mean titer among people living with HIV and healthy controls.; Figure S3: The incidence rates of adverse events among people living with HIV; Figure S4: Sensitivity analysis of seroconversion rates by excluding studies with a high risk of bias.; Figure S5: Sensitivity analysis of risk ratio of seroconversion by excluding studies with a high risk of bias.; Figure S6: Sensitivity analysis of incidence rates of adverse events by excluding studies with a high risk of bias.; Figure S7: Sensitivity analysis of seroconversion rates by excluding studies with the number of people living with HIV less than 100; Figure S8: Sensitivity analysis of risk ratio of seroconversion by excluding studies with the number of people living with HIV less than 100; Figure S9 Sensitivity analysis of incidence rates of adverse events by excluding studies with the number of people living with HIV less than 100; Figure S10: The publication bias of studies on seroconversion rates among people living with HIV after a first or second dose of COVID-19 vaccine; Figure S11: The publication bias of studies on seroconversion among people living with HIV compared with healthy controls after a first or second dose of COVID-19 vaccine; Figure S12: The publication bias of studies on incidence rates of adverse events among people living with HIV after a first or second dose of COVID-19 vaccine; Table S1: Characteristics and basic information of the studies included in the systematic review and meta-analysis for COVID-19 vaccine immunogenicity; Table S2: Characteristics and basic information of the studies included in the systematic review and meta-analysis for COVID-19 vaccine immunogenicity; Table S3: Risk of bias of all included randomized clinical trials using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2); Table S4: Risk of bias of all included non-randomized clinical trials using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool; Table S5: Risk of bias of all included cohort studies using the Newcastle-Ottawa quality assessment scale; Table S6: Risk of bias of all included case-control studies using the Newcastle-Ottawa quality assessment scale; Table S7: Risk of bias of all included cross-sectional studies using the Agency for Healthcare Research and Quality scale

Author Contributions: Conceptualization, writing—review and editing, and supervision, J.L. and M.L.; literature search, data extraction, and literature quality assessment, L.K., W.S., P.G. and Y.W.; statistical analysis and writing—original draft preparation, L.K. and W.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the National Natural Science Foundation of China (72122001; 71934002), the National Key Research and Development Program of China (2021ZD0114101; 2021ZD0114104; 2021ZD0114105), and the Capital Health Development Scientific Research Project of China (2021-1G-4281). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. No payment was received by any of the co-authors for the preparation of this article.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data can be obtained by contacting the corresponding author.

Acknowledgments: Thanks to all authors for their contributions to this article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 27 May 2022).
2. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. Nat. Med. 2021, 27, 601–615. [CrossRef] [PubMed]
3. Bavel, J.J.V.; Baicker, K.; Boggio, P.S.; Capraro, V.; Cichocka, A.; Cikara, M.; Crockett, M.J.; Crum, A.J.; Douglas, K.M.; Druckman, J.N.; et al. Using social and behavioural science to support COVID-19 pandemic response. Nat. Hum. Behav. 2020, 4, 460–471. [CrossRef] [PubMed]
4. Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [CrossRef]

5. Mirzaei, H.; McFarland, W.; Karamouzian, M.; Sharifi, H. COVID-19 among People Living with HIV: A Systematic Review. AIDS Behav. 2021, 25, 85–92. [CrossRef] [PubMed]

6. Shields, A.M.; Burns, S.O.; Savic, S.; Richter, A.G. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J. Allergy Clin. Immunol. 2021, 147, 870–875.e871. [CrossRef]

7. Geretti, A.M.; Stockdale, A.J.; Kelly, S.H.; Cevik, M.; Collins, S.; Waters, L.; Villa, G.; Docherty, A.; Harrison, E.M.; Turtle, L.; et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization among People with Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin. Infect. Dis. 2021, 73, e2095–e2106. [CrossRef]

8. Ssentongo, P.; Heilbrunn, E.S.; Ssentongo, A.E.; Advani, S.; Chinchilli, V.M.; Nunez, J.J.; Du, P. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: A systematic review and meta-analysis. Sci. Rep. 2021, 11, 6283. [CrossRef]

9. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of [CrossRef]

10. Talic, S.; Shah, S.; Wild, H.; Gasevic, D.; Maharaj, A.; Ademi, Z.; Li, X.; Xu, W.; Mesa-Eguiagaray, I.; Rostron, J.; et al. Effectiveness of public health measures in reducing the incidence of COVID-19, SARS-CoV-2 transmission, and COVID-19 mortality: Systematic review and meta-analysis. BMJ 2021, 375, e068302. [CrossRef]

11. Wang, J.; Lyu, Y.; Zhang, H.; Jing, R.; Lai, X.; Feng, H.; Knoll, M.D.; Fang, H. Willingness to pay and financing preferences for COVID-19 vaccination in China. Vaccine 2021, 39, 1968–1976. [CrossRef]

12. Skowronski, D.M.; De Serres, G. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2021, 384, 1576–1577. [CrossRef] [PubMed]

13. Moreira, E.D., Jr.; Kitchin, N.; Xu, X.; Dychter, S.S.; Lockhart, S.; Gurtman, A.; Perez, J.L.; Zerbini, C.; Jennings, T.W.; et al. Safety and Efficacy of a Third Dose of BNT162b2 COVID-19 Vaccine. N. Engl. J. Med. 2021, 386, 1910–1921. [CrossRef] [PubMed]

14. Dunkle, L.M.; Kotloff, K.L.; Gay, C.L.; Áñez, G.; Adelglass, J.M.; Barrat Hernández, A.Q.; Harper, W.L.; Duncanson, D.M.; McArthur, M.A.; Florescu, D.F.; et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N. Engl. J. Med. 2022, 386, 531–543. [CrossRef]

15. Vallée, A.; Fourn, E.; Majerholc, C.; Touche, P.; Zucman, D. COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines 2021, 9, 302. [CrossRef]

16. Bogart, L.M.; Ojikutu, B.O.; Tyagi, K.; Klein, D.J.; Mutchler, M.G.; Dong, L.; Lawrence, S.J.; Thomas, D.R.; Kellman, S. COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy among Black Americans Living with HIV. J. Acquir. Immune Defic. Syndr. 2021, 86, 200–207. [CrossRef] [PubMed]

17. Chai, R.; Yang, J.; Zhang, X.; Huang, X.; Yu, M.; Fu, G.; Lan, G.; Qiao, Y.; Li, S.; Yao, Y.; et al. Reasons of COVID-19 Vaccine Hesitancy among Chinese People Living with HIV/AIDS: A Structural Equation Modeling Analysis. JMIR Public Health Surveill. 2022, 8, e39955. [CrossRef]

18. Han, X.; Yu, X.; Han, Y.; Fang, Q.; Shen, C.; Liu, H.; Wang, P.; Wang, Y.; Li, X. Safety and Immunogenicity of Inactivated COVID-19 Vaccines among People Living with HIV in China. Infect. Drug Resist. 2022, 15, 2091–2100. [CrossRef]

19. Touizer, E.; Alrubayyi, A.; Rees-Spear, C.; Fisher-Pearson, N.; Griffith, S.A.; Muir, L.; Pellegrino, P.; Waters, L.; Burns, F.; Kinloch, S.; et al. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. Lancet HIV 2021, 8, e317–e318. [CrossRef]

20. Levy, I.; Wieder-Finesod, A.; Litchevsky, V.; Biber, A.; Indenbaum, V.; Olmer, L.; Huppert, A.; Mor, O.; Goldstein, M.; Levin, E.G.; et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin. Microbiol. Infect. 2021, 27, 1851–1855. [CrossRef]

21. Noe, S.; Ochana, N.; Wiese, C.; Schabaz, F.; Von Krosigk, A.; Heldwein, S.; Rasshofer, R.; Wolf, E.; Jonsson-Oldenburg, C. Humoral response to SARS-CoV-2 vaccines in people living with HIV. Infection 2021, 50, 617–623. [CrossRef]

22. González de Aledo, M.; Cañizares, A.; Vázquez-Rodríguez, P.; Castro, Á.; Moldes, L.; López, S.; Miguez, E.; Bou, G.; Mena, Á. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV. AIDS 2022, 36, 691–695. [CrossRef] [PubMed]

23. Madhi, S.A.; Koen, A.L.; Izu, A.; Fairlie, L.; Cutland, C.L.; Baillie, V.; Padayachee, S.D.; Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV 2021, 8, e568–e580. [CrossRef]

24. Ruddy, J.A.; Boyarsky, B.J.; Bailey, J.R.; Karaba, A.H.; Garonziki-Wang, J.M.; Segev, D.L.; Durand, C.M.; Werbel, W.A. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS 2021, 35, 2399–2401. [CrossRef] [PubMed]

25. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Bouton, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [CrossRef]
26. Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect. Dis.* 2022, 21, 181–192. [CrossRef]

27. Haas, J.W.; Bender, F.L.; Bailou, S.; Kelley, J.M.; Wilhelm, M.; Miller, F.G.; Rief, W.; Kapichuk, T.J. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis. *JAMA Netw. Open* 2022, 5, e2143955. [CrossRef]

28. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2. A revised tool for assessing risk of bias in randomised trials. *BMJ* 2019, 366, l4898. [CrossRef]

29. Sterne, J.A.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016, 355, i4919. [CrossRef]

30. Wells, G.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-Analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 12 April 2022).

31. Rostom, A.; Dubé, C.; Cranney, A.; Saloojee, N.; Sy, R.; Garrity, C.; Sampson, M.; Zhang, L.; Yazdi, F.; Mamaladze, V.; et al. Appendix D. Quality Assessment Forms. In *Celiac Disease: Evidence Reports/Technology Assessments, No. 104; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, September 2004*. Available online: https://www.ncbi.nlm.nih.gov/books/NBK35156/ (accessed on 24 May 2022).

32. Borenstein, M.; Hedges, L.V.; Higgins, J.P.; Rothstein, H.R. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res. Synth. Methods* 2010, 1, 97–111. [CrossRef]

33. Muka, T.; Glisic, M.; Milic, J.; Verhoog, S.; Bohlius, J.; Bramer, W.; Chowdhury, R.; Franco, O.H. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. *Eur. J. Epidemiol.* 2020, 35, 49–60. [CrossRef]

34. Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* 2002, 21, 1539–1558. [CrossRef]

35. Beaudry, G.; Yu, R.; Perry, A.E.; Fazel, S. Effectiveness of psychological interventions in prison to reduce recidivism: A systematic review and meta-analysis of randomised controlled trials. *Lancet Psychiatry* 2021, 8, 759–773. [CrossRef]

36. Duval, S.; Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometers* 2000, 56, 455–463. [CrossRef] [PubMed]

37. Antinori, A.; Cicalini, S.; Meschi, S.; Bordoni, V.; Lorenzini, P.; Vergori, A.; Lanini, S.; De Pascale, L.; Matusali, G.; Mariotti, D.; et al. Humoral and cellular immune response elicited by mRNA vaccination against SARS-CoV-2 in people living with HIV (PLWH) receiving antiretroviral therapy (ART) according with current CD4 T-lymphocyte count. *Clin. Infect. Dis.* 2022, 75, e552–e563. [CrossRef]

38. Balcells, M.E.; Le Corre, N.; Durán, J.; Ceballos, M.E.; Vizcaya, C.; Mondaca, S.; Dib, M.; Rabagliati, R.; Sarmiento, M.; Burgos, P.I.; et al. Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile. *Clin. Infect. Dis.* 2022, 75, e594–e602. [CrossRef] [PubMed]

39. Brumme, Z.L.; Mwimani, F.; Lapointe, H.R.; Cheung, P.K.; Sang, Y.; Duncan, M.C.; Yaseen, F.; Agafitei, O.; Ennis, S.; Ng, K.; et al. Humoral immune responses to COVID-19 vaccine in people living with HIV receiving suppressive antiretroviral therapy. *NPJ Vaccines* 2022, 7, 28. [CrossRef] [PubMed]

40. Feng, Y.; Zhang, Y.; He, Z.; Huang, H.; Tian, X.; Wang, G.; Chen, D.; Ren, Y.; Jia, L.; Wang, W.; et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: A non-randomized cohort study. *EClinicalMedicine* 2022, 43, 101226. [CrossRef]

41. Haidar, G.; Agha, M.; Bilderback, A.; Lukanski, A.; Linstrum, K.; Troyan, R.; Rothenberger, S.; McMahon, D.K.; Crandall, M.D.; Sobolewski, M.D.; et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: The COVCIS study. *Clin. Infect. Dis.* 2022, 75, e630–e644. [CrossRef] [PubMed]

42. Hassold, N.; Brichler, S.; Ouedraogo, E.; Leclerc, D.; Carroue, S.; Gater, Y.; Alloui, C.; Carbonnelle, E.; Bouchaud, O.; Mechai, F.; et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. *Aids* 2022, 36, F1–F5. [CrossRef]

43. Heftdal, L.D.; Knudsen, A.D.; Hansen, C.B.; Møller, D.L.; Pries-Heje, M.; Fogh, K.; Hasselbalch, R.B.; Jarlhet, I.; Pérez-Alós, L.; et al. Humoral response to two doses of BNT162b2 vaccination in people with HIV. *J. Intern. Med.* 2022, 291, 513–518. [CrossRef]

44. Huang, X.; Yan, Y.; Su, B.; Xiao, D.; Yu, M.; Jin, X.; Duan, J.; Zhang, X.; Zheng, S.; Fang, Y.; et al. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. *Viruses* 2022, 14, 277. [CrossRef] [PubMed]

45. Jedicke, N.; Stankov, M.V.; Cossmann, A.; Dopfer-Jablonska, A.; Knuth, C.; Ahrenstorff, G.; Ramos, G.M.; Behrens, G.M.N. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. *HIV Med.* 2022, 23, 558–563. [CrossRef] [PubMed]
47. Liu, Y.; Han, J.; Li, X.; Chen, D.; Zhao, X.; Qiu, Y.; Zhang, L.; Xiao, J.; Li, B.; Zhao, H. COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. *Vaccines* 2021, 9, 1458. [CrossRef]

48. Lv, Z.; Li, Q.; Feng, Z.; Zheng, X.; Yin, N.; Yang, H.; Gu, Q.; Ying, S.; Qi, Y.; Li, X.; et al. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV. *Int. Immunopharmacol.* 2022, 102, 108383. [CrossRef]

49. Nault, L.; Marchitto, L.; Goyette, G.; Tremblay-Sher, D.; Fortin, C.; Martel-Laferrière, V.; Trottier, B.; Richard, J.; Durand, M.; Kaufmann, D.; et al. COVID-19 vaccine immunogenicity in people living with HIV-1. *Vaccine* 2022, 40, 3633–3637. [CrossRef]

50. Ogbe, A.; Face, M.; Bittaye, M.; Tipoe, T.; Adele, S.; Alagaratnam, J.; Aley, P.K.; Ansari, M.A.; Bara, A.; Broadhead, S.; et al. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. *JCI Insight* 2022, 7, e157031. [CrossRef]

51. Oyaert, M.; De Scheerder, M.A.; Van Herreweghe, S.; Laureys, G.; Van Assche, S.; Cambron, M.; Naesens, L.; Hoste, L.; Claes, K.; Haerynck, F.; et al. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients. *Front. Immunol.* 2022, 13, 858399. [CrossRef]

52. Spinelli, M.A.; Peluso, M.J.; Lynch, K.L.; Gildden, D.V.; Henrich, T.J.; Deeks, S.G.; Gandhi, M. Differences in Post-mRNA Vaccine SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: A Matched Case-Control Observational Study. *Clin. Infect. Dis.* 2021, 75, e916–e919. [CrossRef]

53. Tuan, J.J.; Zapata, H.; Critch-Gilfillan, T.; Ryall, L.; Turcotte, B.; Mutic, S.; Andrews, L.; Roh, M.E.; Friedland, G.; Barakat, L.; et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. *HIV Med.* 2022, 23, 178–185. [CrossRef]

54. Woldemeskel, B.A.; Karaba, A.H.; Garliss, C.C.; Beck, E.J.; Wang, K.H.; Laeyendecker, O.; Cox, A.L.; Blankson, J.N. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV). *Clin. Infect. Dis.* 2022, 74, 1268–1270. [PubMed]

55. Wong, N.S.; Wong, B.C.K.; Chan, J.M.C.; Wong, K.H.; Tsang, O.T.Y.; Mok, C.K.P.; Hui, D.S.C.; Lee, S.S.; Chan, D.P.C. Surrogate neutralisation responses following SARS-CoV-2 vaccine in people living with HIV—Comparison between inactivated and mRNA vaccine. *Aids* 2022, 36, 1255–1264. [CrossRef] [PubMed]

56. Milano, E.; Ricciardi, A.; Casciaro, R.; Pallara, E.; De Vita, E.; Bavaro, D.F.; Larocca, A.M.V.; Stefanizzi, P.; Tafuri, S.; Saracino, A. Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy. *J. Med. Virol.* 2022, 94, 2230–2236. [CrossRef] [PubMed]

57. Wu, S.; Zhang, Y.; Ming, F.; Zou, S.; Wu, M.; Guo, W.; Tang, W.; Liang, K. Adverse events of inactivated COVID-19 vaccine in HIV-infected adults. *AIDS Res. Ther.* 2021, 18, 92. [CrossRef] [PubMed]

58. Ao, L.; Lu, T.; Cao, Y.; Chen, Z.; Wang, Y.; Li, Z.; Ren, X.; Xu, P.; Peng, M.; Chen, M.; et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV. *Emerg. Microbes Infect.* 2022, 11, 1126–1134. [CrossRef]

59. Bergman, P.; Blennow, O.; Hansson, L.; Mielke, S.; Nowak, P.; Chen, P.; Söderdahl, G.; Österborg, A.; Smith, C.; Wullimann, D.; et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EClinicalMedicine* 2022, 74, 103705. [CrossRef]

60. Frater, J.; Ewer, K.J.; Ogbe, A.; Face, M.; Adele, S.; Adland, E.; Alagaratnam, J.; Aley, P.K.; Ali, M.; Ansari, M.A.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: A single-arm substudy of a phase 2/3 clinical trial. *Lancet HIV* 2022, 9, e474–e485. [CrossRef]

61. Netto, L.C.; Ibrahim, K.Y.; Picone, C.M.; Alves, A.; Aniceto, E.V.; Santiago, M.R.; Parmeiani, P.S.S.; Aikawa, N.E.; Medeiros-Ribeiro, A.C.; Pasoto, S.G.; et al. Safety and immunogenicity of CoronaVac in people living with HIV: A prospective cohort study. *Lancet HIV* 2022, 9, e323–e331. [CrossRef]

62. Rahav, G.; Lustig, Y.; Lavee, J.; Ohad, B.; Magen, H.; Hod, T.; Noga, S.-T.; Shmueli, E.S.; Droiit, M.; Ben-Ari, Z.; et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. *EClinicalMedicine* 2021, 41, 101158. [CrossRef]

63. Speich, B.; Chammartin, F.; Abela, I.A.; Amico, P.; Stoeckle, M.P.; Eichenberger, A.L.; Hasse, B.; Braun, D.L.; Schuermann, M.M.; Müller, T.F.; et al. Antibody response in immunocompromised patients after the administration of SARS-CoV-2 vaccine BNT162b2 or mRNA-1273: A randomised controlled trial. *Clin. Infect. Dis.* 2022, 75, e585–e593. [CrossRef]

64. Portillo, V.; Fedeli, C.; Ustero Alonso, P.; Petignat, I.; Mereles Costa, E.S.; Sulstarova, A.; Jaksic, C.; Yerly, S.; Calmy, A. Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccine in HIV-Infected Individuals. *Front. Immunol.* 2021, 12, 820126. [CrossRef] [PubMed]

65. Lee, A.; Wong, S.Y.; Chai, L.Y.A.; Lee, S.C.; Lee, M.X.; Muthiah, M.D.; Tay, S.H.; Teo, C.B.; Tan, B.K.J.; Chan, Y.H.; et al. Efficacy of COVID-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. *BMJ* 2022, 376, e068632. [CrossRef] [PubMed]

66. Cheng, H.; Peng, Z.; Luo, W.; Si, S.; Mo, M.; Zhou, H.; Xin, X.; Liu, H.; Yu, Y. Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. *Vaccines* 2021, 9, 582. [CrossRef] [PubMed]

67. El Chaer, F.; El Sahly, H.M. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. *Am. J. Med.* 2019, 132, 437–446. [CrossRef]